Delayed
Japan Exchange
02:00:00 2024-05-14 EDT
5-day change
1st Jan Change
2,273
JPY
+21.36%
+23.87%
+13.14%
I'rom Group Co., Ltd. authorizes a Buyback Plan.
The Board of Directors of I'rom Group Co., Ltd. has authorized a buyback plan on November 8, 2018.
I'rom Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-11
CI
Lupin Ties Up with I'rom Group to Commercialize Denosumab in Japan
22-08-25
MT
Lupin and I'rom Enter into an Exclusive Licensing Agreement for Denosumab Biosimilar for Japan
22-08-25
CI
Cogsmart Co., Ltd. announced that it has received ¥350 million in funding from Omron Ventures Co., Ltd., I'rom Group Co., Ltd., DG Daiwa Ventures Inc., IT-Farm Corporation, Makoto Capital Co., Ltd. and other investors
22-01-05
CI
I'rom Group Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2021, Payable June 29, 2021 and Provided Dividend Guidance for the Second Quarter and Fiscal Year 2022
21-05-10
CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2020; Provides Year End Dividend for the Year Ending March 31, 2020
20-02-05
CI
Tranche Update on I'rom Group Co., Ltd.'s Equity Buyback Plan announced on February 26, 2019.
19-03-06
CI
I'rom Group Co., Ltd.'s Equity Buyback announced on February 26, 2019 has expired with 124,300 shares for ¥199.89 million.
19-03-04
CI
I'rom Group Co., Ltd. announces an Equity Buyback for 130,000 shares, representing 1.12% for ¥200 million.
19-02-26
CI
I'rom Group Co., Ltd. authorizes a Buyback Plan.
19-02-25
CI
Tranche Update on I'rom Group Co., Ltd.'s Equity Buyback Plan announced on November 8, 2018.
18-11-29
CI
I'rom Group Co., Ltd.'s Equity Buyback announced on November 8, 2018 has expired with 89,800 shares for ¥199.86 million.
18-11-28
CI
I'rom Group Co., Ltd. announces an Equity Buyback for 110,000 shares, representing 0.94% for ¥200 million.
18-11-08
CI
I'rom Group Co., Ltd. authorizes a Buyback Plan.
18-11-07
CI
I'rom Group Co., Ltd.(TSE:2372) added to S&P Global BMI Index
18-09-24
CI
An undisclosed buyer cancelled the acquisition of I'rom OK Co., Ltd. from I'rom Group Co., Ltd..
18-05-25
CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2018
18-02-07
CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 2018; Declares Dividend for the Second Quarter of Fiscal 2018, Payable on December 15, 2017
17-11-08
CI
OKEIOS Co., Ltd. announced that it has received funding from I'rom Group Co., Ltd.
17-10-16
CI
I'rom Group Co., Ltd. completed the acquisition CMAX Clinical Research Pty Ltd from IDT Australia Limited for AUD 16.2 million.
17-08-22
CI
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018
17-08-08
CI
An undisclosed buyer signed a contract to acquire I'rom OK Co., Ltd. from I'rom Group Co., Ltd. for ¥810 million.
17-05-25
CI
I'rom Group Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Full Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2018
17-05-11
CI
I'rom Plans To Acquire DSU
17-03-31
CI
I'rom Group Co., Ltd. entered into contract to acquire Ethic Co., Ltd. from Yasutomo Yamauchi, Shitotomo Yamauchi, and other sellers for ¥96.8 million.
17-03-30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
More about the company
1st Jan change
Capi.
+13.14% 145M -14.93% 8.58B +63.16% 4.12B -3.34% 2.48B -9.81% 2.44B -43.01% 2.29B -4.82% 2B -18.74% 1.53B -40.24% 1.21B +9.42% 1.12B
Medical & Diagnostic Laboratories
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1